These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 15920941)

  • 1. Measurements of plasma oxycodone, noroxycodone and oxymorphone levels in a patient with bilateral nephrectomy who is undergoing haemodialysis.
    Lee MA; Leng ME; Cooper RM
    Palliat Med; 2005 Apr; 19(3):259-60. PubMed ID: 15920941
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dialyzability of Oxycodone and Its Metabolites in Chronic Noncancer Pain Patients with End-Stage Renal Disease.
    Samolsky Dekel BG; Donati G; Vasarri A; Croci Chiocchini AL; Gori A; Cavallari G; Di Nino G; Mercolini L; Protti M; Mandrioli R; Melotti RM; La Manna G
    Pain Pract; 2017 Jun; 17(5):604-615. PubMed ID: 27589376
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The use of liquid chromatography/mass spectrometry for quantitative analysis of oxycodone, oxymorphone and noroxycodone in Ringer solution, rat plasma and rat brain tissue.
    Boström E; Jansson B; Hammarlund-Udenaes M; Simonsson US
    Rapid Commun Mass Spectrom; 2004; 18(21):2565-76. PubMed ID: 15468158
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of oxycodone/naloxone and its metabolites in patients with end-stage renal disease during and between haemodialysis sessions.
    Leuppi-Taegtmeyer A; Duthaler U; Hammann F; Schmid Y; Dickenmann M; Amico P; Jehle AW; Kalbermatter S; Lenherr C; Meyer Zu Schwabedissen HE; Haschke M; Liechti ME; Krähenbühl S
    Nephrol Dial Transplant; 2019 Apr; 34(4):692-702. PubMed ID: 30189012
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Determination of oxycodone, noroxycodone, oxymorphone, and noroxymorphone in human plasma by liquid chromatography-electrospray-tandem mass spectrometry.
    Neuvonen M; Neuvonen PJ
    Ther Drug Monit; 2008 Jun; 30(3):333-40. PubMed ID: 18520605
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Determination of oxycodone, noroxycodone and oxymorphone by high-performance liquid chromatography-electrospray ionization-tandem mass spectrometry in human matrices: in vivo and in vitro applications.
    Fang WB; Lofwall MR; Walsh SL; Moody DE
    J Anal Toxicol; 2013; 37(6):337-44. PubMed ID: 23743505
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cancer cachexia raises the plasma concentration of oxymorphone through the reduction of CYP3A but not CYP2D6 in oxycodone-treated patients.
    Naito T; Tashiro M; Ishida T; Ohnishi K; Kawakami J
    J Clin Pharmacol; 2013 Aug; 53(8):812-8. PubMed ID: 23733622
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low-level quantitation of oxycodone and its oxidative metabolites, noroxycodone, and oxymorphone, in rat plasma by high-performance liquid chromatography-electrospray ionization-tandem mass spectrometry.
    Edwards SR; Smith MT
    J Chromatogr B Analyt Technol Biomed Life Sci; 2007 Apr; 848(2):264-70. PubMed ID: 17098487
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic-pharmacodynamic relationships of controlled-release oxycodone.
    Kaiko RF; Benziger DP; Fitzmartin RD; Burke BE; Reder RF; Goldenheim PD
    Clin Pharmacol Ther; 1996 Jan; 59(1):52-61. PubMed ID: 8549034
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of a sensitive method for the determination of oxycodone and its major metabolites noroxycodone and oxymorphone in human plasma by liquid chromatography-tandem mass spectrometry.
    Gaudette F; Sirhan-Daneau A; St-Onge M; Turgeon J; Michaud V
    J Chromatogr B Analyt Technol Biomed Life Sci; 2016 Jan; 1008():174-180. PubMed ID: 26655109
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sex differences in the pharmacokinetics, oxidative metabolism and oral bioavailability of oxycodone in the Sprague-Dawley rat.
    Chan S; Edwards SR; Wyse BD; Smith MT
    Clin Exp Pharmacol Physiol; 2008 Mar; 35(3):295-302. PubMed ID: 17973932
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of aprepitant on the pharmacokinetics of controlled-release oral oxycodone in cancer patients.
    Fujiwara Y; Toyoda M; Chayahara N; Kiyota N; Shimada T; Imamura Y; Mukohara T; Minami H
    PLoS One; 2014; 9(8):e104215. PubMed ID: 25121773
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The pharmacokinetics of oxycodone in uremic patients undergoing renal transplantation.
    Kirvela M; Lindgren L; Seppala T; Olkkola KT
    J Clin Anesth; 1996 Feb; 8(1):13-8. PubMed ID: 8695073
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influences on the pharmacokinetics of oxycodone: a multicentre cross-sectional study in 439 adult cancer patients.
    Andreassen TN; Klepstad P; Davies A; Bjordal K; Lundström S; Kaasa S; Dale O
    Eur J Clin Pharmacol; 2011 May; 67(5):493-506. PubMed ID: 21140139
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of oxycodone pharmacokinetics after buccal and sublingual administration in children.
    Kokki H; Rasanen I; Lasalmi M; Lehtola S; Ranta VP; Vanamo K; Ojanperä I
    Clin Pharmacokinet; 2006; 45(7):745-54. PubMed ID: 16802855
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CYP2D6 genotype dependent oxycodone metabolism in postoperative patients.
    Stamer UM; Zhang L; Book M; Lehmann LE; Stuber F; Musshoff F
    PLoS One; 2013; 8(3):e60239. PubMed ID: 23555934
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tentative identification of novel oxycodone metabolites in human urine.
    Moore KA; Ramcharitar V; Levine B; Fowler D
    J Anal Toxicol; 2003 Sep; 27(6):346-52. PubMed ID: 14516487
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CYP3A5*3 affects plasma disposition of noroxycodone and dose escalation in cancer patients receiving oxycodone.
    Naito T; Takashina Y; Yamamoto K; Tashiro M; Ohnishi K; Kagawa Y; Kawakami J
    J Clin Pharmacol; 2011 Nov; 51(11):1529-38. PubMed ID: 21209234
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oxycodone findings and CYP2D6 function in postmortem cases.
    Jakobsson G; Larsson R; Pellè L; Kronstrand R; Gréen H
    Forensic Sci Int Genet; 2021 Jul; 53():102510. PubMed ID: 33799050
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of the pharmacokinetics of oxycodone and noroxycodone in male dark agouti and Sprague--Dawley rats: influence of streptozotocin-induced diabetes.
    Huang L; Edwards SR; Smith MT
    Pharm Res; 2005 Sep; 22(9):1489-98. PubMed ID: 16132361
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.